Human Tissue Studies / Translational Validation
This validation study translates findings from the basic mechanism study "Membrane-Driven Alpha-Synuclein Nucleation" into a physiologically relevant human cellular model. The parent study identified that specific membrane lipid compositions—particularly those enriched in anionic phospholipids like phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2)—dramatically accelerate alpha-synuclein nucleation through charge-mediated interactions. This experiment validates whether these in vitro findings translate to increased cellular toxicity in human iPSC-derived dopaminergic neurons and whether membrane-targeting small molecules can block this pathogenic process.
Aim 1: Validate lipid composition-toxicity relationship in iPSC-derived neurons
Aim 2: Validate membrane-targeting small molecule inhibitors
Aim 3: Compare disease model susceptibility
| Line Type | Source | Genetic Background |
|---|---|---|
| Healthy Control 1 | WiCell | Wild-type |
| Healthy Control 2 | Cedars-Sinai | Wild-type |
| PD Patient 1 | Cedars-Sinai | LRRK2 G2019S |
| PD Patient 2 | Cedar-Sinai | LRRK2 G2019S |
| PD Patient 3 | WiCell | SNCA multiplication |
| PD Patient 4 | Coriell | A53T mutation |
| Formulation | Composition | Expected Nucleation Effect |
|---|---|---|
| Control | POPC (100%) | Baseline |
| Low PS | POPC:POPS (80:20) | Moderate acceleration |
| High PS | POPC:POPS (60:40) | High acceleration |
| PIP2 | POPC:POPS:PIP2 (55:35:10) | Very high acceleration |
| Disease-like | POPC:POPS:PIP2:Cholesterol (45:30:10:15) | Maximum acceleration |
| Compound | Target | Source | Known IC50 |
|---|---|---|---|
| CLR01 | Membrane/Protein | Tolerant | ~10 μM |
| Anle138b | Oligomers | MedChemExpress | ~3 μM |
| Small Molecule 1* | PS binding | From parent study | TBD |
| Small Molecule 2* | PIP2 binding | From parent study | TBD |
*Compounds identified from the parent mechanism study structural analysis
| Category | Items | Cost (USD) |
|---|---|---|
| iPSC Lines | 6 lines (2 HC + 4 PD) | $18,000 |
| Differentiation Reagents | Growth factors, media, antibodies | $45,000 |
| Liposome Synthesis | Lipids, extrusion supplies | $12,000 |
| Small Molecule Library | 4 compounds, dose-response | $8,000 |
| Viability Assays | MTS, ATP, ELISA kits | $15,000 |
| Immunostaining | Antibodies, reagents | $18,000 |
| Electrophysiology | mEPSC recordings | $25,000 |
| RNA-seq | Library prep, sequencing (12 samples) | $24,000 |
| Personnel | Postdoc 25% effort, 18 months | $67,500 |
| Equipment | Microscope access, patch clamp | $30,000 |
| TOTAL | $262,500 |
| Phase | Duration | Activities |
|---|---|---|
| Phase 1: Setup | Months 1-3 | Obtain iPSC lines, establish differentiation protocol, synthesize liposomes |
| Phase 2: Toxicity Validation | Months 4-9 | Aim 1 experiments, dose-response curves, biomarker validation |
| Phase 3: Inhibitor Testing | Months 7-12 | Aim 2 experiments, compound optimization, therapeutic window |
| Phase 4: Disease Comparison | Months 10-15 | Aim 3 experiments, RNA-seq, comparative analysis |
| Phase 5: Analysis | Months 14-18 | Data integration, manuscript preparation |
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Value | 9 | Direct validation of basic mechanism in human neurons |
| Feasibility | 8 | Established iPSC protocols, reasonable timeline |
| Novelty | 9 | First systematic validation of membrane-nucleation in human cells |
| Disease Impact | 10 | Critical for translating basic findings to therapy |
| Reach | 8 | Findings applicable to all synucleinopathies |
| Cost Efficiency | 9 | Significant data per dollar, uses existing infrastructure |
| Time Efficiency | 7 | 18 months is reasonable for comprehensive validation |
| Evidence Base | 9 | Builds on strong basic mechanism data |
| Addresses Uncertainty | 10 | Directly tests key unknown: in vivo relevance |
| Translation Potential | 10 | Essential step for drug development |
Total Score: 89/140